Oculis Holding AG (OCS)
NASDAQ: OCS · Real-Time Price · USD
7.29
-0.11 (-1.49%)
Oct 16, 2026, 4:00 PM EDT - Market closed
Oculis Holding AG Revenue
Oculis Holding AG had revenue of 310.00K CHF in the quarter ending June 30, 2026, with 18.77% growth. This brings the company's revenue in the last twelve months to 1.17M, up 53.33% year-over-year. In the year 2025, Oculis Holding AG had annual revenue of 1.20M with 74.78% growth. That makes Oculis Holding AG the 43,005th largest company in the world by revenue and 5,935th in the United States.
Revenue (ttm)
1.17M CHF
Revenue Growth
+53.33%
P/S Ratio
309.99
Revenue / Employee
19,550 CHF
Employees
60
Market Cap
450.03M USD
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 1.20M | 513.00K | 74.78% |
| Dec 31, 2024 | 686.00K | -197.00K | -22.31% |
| Dec 31, 2023 | 883.00K | -29.00K | -3.18% |
| Dec 31, 2022 | 912.00K | -48.00K | -5.00% |
| Dec 31, 2021 | 960.00K | -33.00K | -3.32% |
| Dec 31, 2020 | 993.00K | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Arvinas | 316.70M |
| REGENXBIO | 174.48M |
| Autolus Therapeutics | 117.39M |
| Allogene Therapeutics | 4.64M |
| YD Bio | 1.24M |
| Neurogene | 925.00K |
| Altimmune | 31.00K |
OCS News
- 11 days ago - Oculis to Highlight Licaminlimab at Eyecelerator @ AAO 2026 and Partner with Neuro-Ophthalmology Subspecialty Day - GlobeNewsWire
- 17 days ago - Oculis Joins the National Multiple Sclerosis Society's Campaign to End MS - GlobeNewsWire
- 17 days ago - Oculis Announces Resignation of Lionel Carnot from Board of Directors - GlobeNewsWire
- 4 weeks ago - Oculis price target raised to $39 from $26 at H.C. Wainwright - TheFly
- 4 weeks ago - Oculis Publishes Notifications of Transactions by Persons Discharging Managerial Responsibilities - GlobeNewsWire
- 4 weeks ago - Oculis Holding AG Transcript: 2026 Global Healthcare Conference - Transcripts
- 4 weeks ago - Oculis Holding AG Transcript: H.C. Wainwright 28th Annual Global Investment Conference - Transcripts
- 7 weeks ago - First Patient Treated in PIONEER-1 Registrational Trial of Privosegtor for Optic Neuritis - GlobeNewsWire